Search Result

Results for "

human DOR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (3) Adenosine Kinase (1) Amino Acid Derivatives (2) Antibiotic (1) Antifolate (3) Apoptosis (7) Aurora Kinase (1) Autophagy (1) Bacterial (6) Bcl-2 Family (3) Biochemical Assay Reagents (3) Cannabinoid Receptor (2) Caspase (3) CCR (1) CD28 (1) CD44 (1) CDK (2) CMV (2) Collagen (1) Constitutive Androstane Receptor (1) Cyclic GMP-AMP Synthase (1) DNA/RNA Synthesis (3) Dopamine Receptor (1) Dopamine Transporter (1) Drug Derivative (1) Drug Intermediate (2) Drug Metabolite (2) E1/E2/E3 Enzyme (1) ELOVL (1) Endogenous Metabolite (2) Endonuclease (1) Enterovirus (1) Environmental Pollutants (1) Epoxide Hydrolase (1) ERK (1) Estrogen Receptor/ERR (1) Fungal (1) GABA Receptor (2) GCGR (2) GLUT (1) Glycosidase (2) GPR109A (1) HCV (1) HDAC (1) Histone Acetyltransferase (1) HIV (1) hnRNP (1) HSP (1) HSV (2) IAP (1) iGluR (1) Integrin (2) Interleukin Related (10) Isotope-Labeled Compounds (1) JNK (1) KMO (1) LDLR (1) Liposome (2) Lipoxygenase (1) LPL Receptor (1) mAChR (1) MCHR1 (GPR24) (2) MDM-2/p53 (1) MEK (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (1) mRNA (1) Natriuretic Peptide Receptor (NPR) (1) Neurokinin Receptor (1) NF-κB (2) NOD-like Receptor (NLR) (2) Opioid Receptor (3) Orphan GPCR (1) p38 MAPK (1) PAI-1 (2) Parasite (5) PGE synthase (2) Phosphatase (1) Phospholipase (1) PI4K (2) PKA (1) Potassium Channel (2) Progesterone Receptor (1) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) PROTACs (1) Protease Activated Receptor (PAR) (1) PSMA (1) PTHR (1) RAD51 (1) Reactive Oxygen Species (ROS) (1) Reference Standards (6) Reverse Transcriptase (1) RIP kinase (2) SARS-CoV (1) Ser/Thr Protease (5) SGLT (1) STING (1) TGF-β Receptor (2) Thrombin (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Topoisomerase (1) Transferrin Receptor (1) TRP Channel (3) VEGFR (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (9) Endocrinology (4) Infection (18) Inflammation/Immunology (37) Metabolic Disease (15) Neurological Disease (20)
Oligonucleotides:	mRNA (1) Interleukin & Receptors (1)

121

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Lometrexol 3 Publications Verification DDATHF	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

Gitogenin 2 Publications Verification	Glycosidase	Metabolic Disease
Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC₅₀ values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .

*(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat)*	PTHR	Metabolic Disease
(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent PTH-1R antagonist and does not display any partial agonist activity .

MMV390048 3 Publications Verification	Parasite PI4K	Infection
MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (K_d ^app=0.3 µM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns. MMV390048 is an antimalarial agent .

MDA 19 2 Publications Verification BZO-HEXOXIZID	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

MSNBA 1 Publications Verification	GLUT	Metabolic Disease Cancer
MSNBA is a potent and selective GLUT5 fructose transport inhibitor with an IC₅₀ of 0.10 mM. MSNBA does not affect the transport activity of human GLUT1, GLUT2, GLUT3, GLUT4 or bacterial GlcPSe. MSNBA competitively inhibits GLUT5 fructose uptake with a K_i of 3.2 μM in MCF7 cells. MSNBA can be used for the study of cancer or diabetes .

5MPN 3 Publications Verification	Phosphatase	Cancer
5MPN is a first-in-class, potent, orally active and selective 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) inhibitor. 5MPN appears to be a competitive inhibitor of the F6P binding site (K_i=8.6 μM). 5MPN does not inhibit PFK-1 or PFKFB3. 5MPN targets the sugar metabolism of tumors and suppresses proliferation of multiple human cancer cell lines .

Benzamidine 3 Publications Verification	Ser/Thr Protease	Inflammation/Immunology
Benzamidine is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

GPR109 receptor agonist-1	GPR109A	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC₅₀ of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis .

HPGDS inhibitor 1	PGE synthase	Inflammation/Immunology
HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC₅₀s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .

GSK1995057	TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK	Inflammation/Immunology
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Liposome	Cardiovascular Disease
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

Flizasertib GDC-8264	RIP kinase Interleukin Related	Cardiovascular Disease Inflammation/Immunology Endocrinology
Flizasertib (GDC-8264) is an orally active, reversible and selective RIP1 inhibitor with K_i ^app values of 0.00071 μM and 0.0013 μM for human and cynomolgus monkey RIP1 kinase, respectively. Flizasertib blocks RIP1 autophosphorylation but does not affect RIP1 protein stability. Flizasertib inhibits pro-inflammatory cytokines (CCL3, CCL4, and IL-1β) production. Flizasertib results in inhibition of colitis and ileitis. Flizasertib can be used in the research of cardiac surgery-associated acute kidney injury .

GSK 366	KMO	Neurological Disease Inflammation/Immunology
GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC₅₀values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMO’s substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H₂O₂) production and reduces H₂O₂ levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimer’s disease .

*PACAP-38 (31-38), human, mouse, rat*	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat does not bind to the PACAP receptor .

PFM39 1 Publications Verification	Endonuclease	Cancer
PFM39, a Mirin analog, is a potent and selective MRE11 exonuclease inhibitor. PFM39 inhibits phosphate rotation for dsDNA exonuclease activity. PFM39 does not inhibit TmMre11 or human MRE11/MRN endonuclease activity .

Griselimycin	Bacterial	Infection
Griselimycin is a cyclic lipopeptide produced by Streptomyces. Griselimycin specifically binds to the sliding clamp of bacterial DNA polymerase and does not interact with human PCNA. Griselimycin exhibits potent antibacterial activity against Mycobacterium tuberculosis (including drug-resistant strains) and a variety of Gram-negative bacteria .

FIT-039	CDK HSV CMV DNA/RNA Synthesis	Infection
FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC₅₀ of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC₅₀ of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.

Sodium lactate ringer's solution Lactated ringer's solution (LRS)	Biochemical Assay Reagents Collagen HSP	Inflammation/Immunology
Sodium lactate ringer's solution (Lactated ringer's solution (LRS)) is an isotonic crystal intravenous injection and arthroscopic irrigation solution containing racemic sodium lactate and electrolytes such as sodium, potassium, calcium and chloride (130 mEq sodium/L, 274 mOsm/L), which can be used as a cell integrity protectant. Sodium lactate ringer's solution maintains the integrity of human meniscus cells, ensures that they retain normal cell morphology, membrane regularity, size and density, and does not alter the mRNA expression levels of α1 (I) procollagen, α1 (II) procollagen, aggrecan or HSP70. Sodium lactate ringer's solution can be applied to studies related to extracellular fluid deficiency and meniscus tears .

p-APMSF hydrochloride p-Amidinophenylmethylsulfonylfluoride hydrochloride	Ser/Thr Protease	Inflammation/Immunology
p-APMSF (p-Amidinophenylmethylsulfonylfluoride) hydrochloride is a serine protease and trypsin inhibitor with the characteristic of rapid onset of action. p-APMSF hydrochloride reduces the enzymatic hydrolysis of recombinant human G-CSF in rat pulmonary mucosa. Combined intratracheal treatment with p-APMSF hydrochloride and Laureth-9 significantly enhances its absorption efficiency in rat lungs. Following intranasal administration, p-APMSF hydrochloride does not increase the concentration of recombinant human G-CSF in rat plasma, nor does it alter the effect of G-CSF on inducing an increase in total white blood cell count .

SWE101	Epoxide Hydrolase	Metabolic Disease
SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC₅₀s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH .

COQ7-IN-1	Mitochondrial Metabolism	Metabolic Disease
COQ7-IN-1, a highly potent inhibitor of human coenzyme Q (COQ7), interferes with ubiquinone (UQ) synthesis. COQ7-IN-1 does not disturb physiological cell growth of human normal culture cells. COQ7-IN-1 can be used for the research of the balance between UQ supplementation pathways: de novo UQ synthesis and extracellular UQ uptake .

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

ACI-19278	hnRNP	Neurological Disease
ACI-19278 is a TDP-43 PET tracer with an average K_d of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [ ¹⁸F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions .

BAL-1516	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
BAL-1516 is an orally active NLRP3 inhibitor with human NLRP3 K_d of 14.2 nM, mouse NLRP3 K_d of 200 nM, and blood-brain barrier penetration.BAL-1516 binds to a surface groove of the NLRP3 nucleotide-binding domain, contacts FISNA and WHD subdomains, forms three hydrogen bonds to the peripheral β-strand of the triple-ATPase, and does not alter NLRP3 ATP-hydrolysis activity.BAL-1516 shows specificity for NLRP3 over other NOD-like receptors, directly binds mouse NLRP3, and inhibits inflammasome formation in monocytes and microglia .

Jaspamycin 1 Publications Verification 7-CN-7-C-Ino	PKA Parasite	Infection
Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC₅₀ of 6.5 nM and K_d of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity .

GP3269	Adenosine Kinase	Neurological Disease
GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC₅₀ of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .

RI(dl)-2 TFA 1 Publications Verification	RAD51	Cancer
RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC₅₀ of 11.1 μM. RI(dl)-2 TFA does not influence RAD51 binding to ssDNA and inhibits homologous recombination (HR) activity in human cells (IC₅₀ of 3.0 μM) .

Lometrexol hydrate 3 Publications Verification DDATHF hydrate	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) hydrate, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol hydrate can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol hydrate has anticancer activity. Lometrexol hydrate also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

pm26TGF-β1 peptide TFA 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .

VU0467319 VU319	mAChR	Neurological Disease
VU0467319 (Compound VU319) is a highly selective and blood-brain-permeable, orally active M1 positive allosteric modulator (PAM) (EC₅₀: 492 nM). VU0467319 is selective (EC₅₀ > 30 μM) versus M2-5 for both human and rat. VU0467319 improves cognitive impairment in Alzheimer's disease (AD) through central M1 muscarinic receptors. VU0467319 does not induce cholinergic adverse reactions and has potential in AD research .

6-Acetamidohexanoic acid Acexamic acid; 6-Acetamidocaproic acid	Drug Metabolite Drug Intermediate	Inflammation/Immunology Cancer
6-Acetamidohexanoic acid (Acexamic acid; 6-Acetamidocaproic acid) is a metabolite of Hexamethylene bisacetamide (HMBA) (HY-124284) with anti-pulmonary fibrosis activity. 6-Acetamidohexanoic acid does not induce differentiation of human promyelocytic leukemia cells, but is taken up by such cells. 6-Acetamidohexanoic acid serves as a carboxylic acid substrate component for constructing carboxylesterase-responsive near-infrared phototheranostic probes. 6-Acetamidohexanoic acid is applicable to research related to pulmonary fibrosis, refractory hypoxemia and cervical cancer .

HDAC-IN-53	HDAC Apoptosis	Cancer
HDAC-IN-53 is an orally active, and selective HDAC1-3 inhibitor with IC₅₀ values of 47 nM, 125 nM, and 450 nM, respectively. HDAC-IN-53 does not inhibit class II HDACs (HDAC4, 5, 6, 7, 9; IC₅₀>10 μM). HDAC-IN-53 induces caspase-dependent apoptosis. HDAC-IN-53 significantly inhibits the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice bearing MC38 colon cancer .

*GRPP (human)*	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

*PACAP-38 (31-38), human, mouse, rat TFA*	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat TFA does not bind to the PACAP receptor .

Z-Pro-Pro-CHO	Prolyl Endopeptidase (PREP) Parasite	Infection
Z-Pro-Pro-CHO is a potent inhibitor of prolyl oligopeptidase (POP), with extremely high affinity for human prolyl oligopeptidase (HsPOP) (IC₅₀=0.012 μM), and it also effectively inhibits the activity of Schistosoma mansoni prolyl oligopeptidase (SmPOP) (IC₅₀=0.16 μM). Z-Pro-Pro-CHO does not block the phosphorylation of ERK or the production of TNF-α or IFN-γ in immune cells from presensitized mice, nor does it induce harmful phenotypes in cultured Schistosoma mansoni schistosomula. Z-Pro-Pro-CHO only partially inhibits epithelial cell wound healing at extremely high concentrations. Z-Pro-Pro-CHO finds wide application in studies related to schistosomiasis .

Lometrexol disodium 3 Publications Verification DDATHF disodium	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) disodium, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol disodium has anticancer activity. Lometrexol disodium also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

MIDD0301 GL-II-93	GABA Receptor	Inflammation/Immunology
MIDD0301 (GL-II-93) is an orally available, active γ-aminobutyric acid type A receptor (GABA_AR) inhibitor and anti-asthmatic agent. MIDD0301 exhibits biological and immunotoxicological safety in mice and does not affect the number of circulating lymphocytes, monocytes, and granulocytes. MIDD0301 has no significant adverse immune response at repeated doses, which is better than Prednisone (HY-B0214). MIDD0301 relaxes histamine-contracted guinea pig and human airway smooth muscle and is used in the study of bronchoconstrictive diseases .

KKL-40	Bacterial	Infection
KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .

AZ3976	PAI-1	Cardiovascular Disease
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .

ATC0065	MCHR1 (GPR24) 5-HT Receptor	Neurological Disease
ATC0065 is a potent, selective and orally active melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist with an IC₅₀ of 15.7 nM for human MCHR1. ATC0065 does not exhibits significant activity for MCHR2. ATC0065 has anxiolytic and antidepressant activities .

SARS-CoV-2 Mpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective SARS-CoV-2 M ^pro inhibitor with an IC₅₀ of 0.18 μM. SARS-CoV-2 Mpro-IN-6 does not inhibit human cathepsins B, F, K, and L, and caspase 3 .

KOR agonist 4	Opioid Receptor
KOR agonist 4 (compound 39) is an agonist of Kappa Opioid Receptor. KOR agonist 4 is an activator of G-protein signaling. KOR agonist 4 binds with GTPγS with an EC₅₀ of 14 nM and with an E_max of 83 %. KOR agonist 4 demonstrates moderate to high intrinsic clearance in human hepatocytes. KOR agonist 4 exhibits 60- and 810-fold selectivities versus the related mu (MOR) and delta (DOR) opioid receptors. KOR agonist 4 is potential for central nervous system (CNS) disorders research .

SB-203186	5-HT Receptor	Neurological Disease
SB-203186 is a highly selective 5-HT₄ receptor antagonist. SB-203186 exhibits a potent competitive antagonistic effect, with its pK_B value being 8.3 in the isolated right atrium model of piglets. SB-203186 can dose-dependently shift the 5-HT-induced tachycardia curve to the right, and does not inhibit the maximum response. SB-203186 is an efficient 5-HT₄ antagonist in pig and human atria, but has no significant inhibitory effect in rat atria. SB-203186 can be used for the study of diseases such as arrhythmias and abnormal myocardial contraction .

Cat. No.	Product Name

HY-L928

GPCR Targeted Diversity Library

7,115 compounds

G protein-coupled receptors (GPCRs) are membrane proteins in humans and one of the most important targets in drug discovery. Approximately 35% of launched drugs are targeted GPCRs, making them a crucial class of targets in drug discovery.

The orthosteric site of a GPCR is its endogenous ligand’s (such as neurotransmitters or hormones) binding site. This site plays a central role in signal transduction. Small molecules binding to this site typically contain a protonatable amino group, enabling the formation of salt bridges or hydrogen bonds with acidic residues in the binding pocket. In contrast, the allosteric site does not directly initiate signaling but modulates the signal intensity of the GPCR by altering or stabilizing the conformation of the orthosteric site. Small molecules binding to the allosteric site often contain multiple aromatic rings to occupy hydrophobic pockets and achieve their functional effects.

MCE has collected over 7,115 reported bioactive molecules targeting GPCRs, covering Class A, B, and C GPCRs. These small molecules were subjected to AI representation to extract 2D and 3D features. Subsequently, we do screening by AI score based on similarity to identify molecules in diversity library highly similar to the reported bioactive molecules in both 2D and 3D, with a threshold greater than 0.7. Further screening based on cLogP was applied to select molecules with good lipophilicity, which facilitates the binding of small molecules to GPCRs. This diversity library can be widely applied to the discovery of compounds targeting GPCR proteins.

HY-L228

Lipid Metabolite Compound Library

145 compounds

Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health.

One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses.

MCE can offer 145 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Cat. No.	Product Name	Type

HY-158976

Sodium lactate ringer's solution

Lactated ringer's solution (LRS)

Biochemical Assay Reagents

Sodium lactate ringer's solution (Lactated ringer's solution (LRS)) is an isotonic crystal intravenous injection and arthroscopic irrigation solution containing racemic sodium lactate and electrolytes such as sodium, potassium, calcium and chloride (130 mEq sodium/L, 274 mOsm/L), which can be used as a cell integrity protectant. Sodium lactate ringer's solution maintains the integrity of human meniscus cells, ensures that they retain normal cell morphology, membrane regularity, size and density, and does not alter the mRNA expression levels of α1 (I) procollagen, α1 (II) procollagen, aggrecan or HSP70. Sodium lactate ringer's solution can be applied to studies related to extracellular fluid deficiency and meniscus tears .

HY-W087937

Benzamidine hydrochloride hydrate

3 Publications Verification

Benzenecarboximidamide hydrochloride hydrate

Biochemical Assay Reagents

Benzamidine (Benzenecarboximidamide) hydrochloride hydrate is a competitive protease inhibitor that blocks the hydrolytic cleavage of glucagon by plasmin, trypsin and thrombin. Benzamidine hydrochloride hydrate effectively inhibits the degradation of glucagon by relevant proteases during the collection, storage and analysis of human plasma and blood samples. During in vivo metabolism, Benzamidine hydrochloride hydrate undergoes N-hydroxylation and produces multiple metabolites, exhibiting characteristics of delayed excretion or biphasic elimination. Benzamidine hydrochloride hydrate only induces slight single-strand DNA breaks at high concentrations and shows no significant genotoxic potential overall. Benzamidine hydrochloride hydrate may interfere with the detection of some glucagon antisera, but does not affect key antigen-antibody affinity at specific concentrations. Benzamidine hydrochloride hydrate can be used as a stabilizer in glucagon radioimmunoassays to ensure the accuracy and recovery rate of detection results .

HY-W127739

Zineb Zinc ethylene-1, 2-bisdithiocarbamate	Biochemical Assay Reagents
Zineb is an agricultural fungicide of the dithiocarbamate class. Its toxicity is relatively low, and there is little evidence of human harm from exposure. Oxidative stress is one of the main factors contributing to diseases caused by Zineb. Zineb does not alter the activity of any superoxide dismutase enzymes. Catalase (CAT) activity was reduced only by Zineb.

HY-NP0245

Retinoic acid-HSA	Biochemical Assay Reagents
Retinoic acid-HSA is a conjugate of Retinoic acid (HY-14649) and Human serum albumin (HSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells .

HY-163551

BNP peptide/KLH

Biochemical Assay Reagents

The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.

Cat. No.	Product Name	Target	Research Area

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P4385

*(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat)*	PTHR	Metabolic Disease
(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent PTH-1R antagonist and does not display any partial agonist activity .

HY-P1845

*PACAP-38 (31-38), human, mouse, rat*	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat does not bind to the PACAP receptor .

HY-125576

Griselimycin	Bacterial	Infection
Griselimycin is a cyclic lipopeptide produced by Streptomyces. Griselimycin specifically binds to the sliding clamp of bacterial DNA polymerase and does not interact with human PCNA. Griselimycin exhibits potent antibacterial activity against Mycobacterium tuberculosis (including drug-resistant strains) and a variety of Gram-negative bacteria .

HY-P2294A

pm26TGF-β1 peptide TFA 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .

HY-P5074

*GRPP (human)*	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

HY-P1845A

*PACAP-38 (31-38), human, mouse, rat TFA*	Amino Acid Derivatives	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a fragment containing the C-terminal 31-38 fragment of PACAP (1-38), human, ovine, rat (HY-P0221). PACAP-38 (31-38), human, mouse, rat TFA does not bind to the PACAP receptor .

HY-134454

Z-Pro-Pro-CHO	Prolyl Endopeptidase (PREP) Parasite	Infection
Z-Pro-Pro-CHO is a potent inhibitor of prolyl oligopeptidase (POP), with extremely high affinity for human prolyl oligopeptidase (HsPOP) (IC₅₀=0.012 μM), and it also effectively inhibits the activity of Schistosoma mansoni prolyl oligopeptidase (SmPOP) (IC₅₀=0.16 μM). Z-Pro-Pro-CHO does not block the phosphorylation of ERK or the production of TNF-α or IFN-γ in immune cells from presensitized mice, nor does it induce harmful phenotypes in cultured Schistosoma mansoni schistosomula. Z-Pro-Pro-CHO only partially inhibits epithelial cell wound healing at extremely high concentrations. Z-Pro-Pro-CHO finds wide application in studies related to schistosomiasis .

HY-P2294

pm26TGF-β1 peptide	TGF-β Receptor	Inflammation/Immunology
pm26TGF-β1 peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction .

HY-P5836

Citrullinated LL-37 1cit	Interleukin Related Bacterial Enterovirus	Inflammation/Immunology
Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .

HY-P11220

Hs02	Bacterial Interleukin Related	Infection
Hs02 is a cationic amphiphilic antibacterial peptide derived from human proteins, and it is the membrane-active module of the core chimeric peptide Chim2. Hs02 exhibits broad-spectrum and potent antibacterial activity against various human pathogenic bacteria with the MIC for Staphylococcus aureus and Escherichia coli of as low as 2 μM, and the MBC is 2-4 μM. Hs02 primarily kills bacteria by disrupting the integrity of the bacterial cell membrane, and it has a relatively low selectivity for eukaryotic cell membranes. Hs02 induces the release of IL-12 but does not induce the release of IL-6, indicating its potential for pro-inflammatory or immune activation. Hs02 can be used in antibacterial and immunomodulatory research .

HY-P5357

SFNGGP-NH2	Protease Activated Receptor (PAR)	Others
SFNGGP-NH2 is a biological active peptide. (PAR-3 is a high-affinity thrombin receptor. PAR-3 mRNA is expressed in the cutaneous mast cells of humans. Protease-Activated Receptors (PARs) have been studied for their roles in itch and their itch-associated response through histamine-dependent/independent pathways have been reported. PAR-3 has been shown not to induce itching alone but possibly in conjunction with PAR-4. Co-expression of PAR-3 and PAR-4 enhances thrombin action suggesting that PAR-3 alone does not mediate transmembrane signaling but instead functions as a cofactor to activate PAR-4.)

HY-P4096A

Cys-HAP-1	Peptides	Inflammation/Immunology
Cys-HAP-1 is a synovium-homing peptide that specifically binds to human and rabbit fibroblast-like synoviocytes, and does not bind to human umbilical vein endothelial cells regardless of TNF-α treatment. Cys-HAP-1 enables targeted drug delivery to inflamed joints after conjugation with liposomes loaded with anti-arthritic agents. Cys-HAP-1 can be used in studies related to adjuvant arthritis .

HY-P11621

JWP24	E1/E2/E3 Enzyme	Cancer
JWP24 is the first cell membrane-permeable peptide inhibitor of MAGE-A4, with an IC₅₀ of 200 nM against human MAGE-A4. JWP24 binds to intracellular targets while retaining binding activity, disrupts the interaction between MAGE-A4 and RAD18, and does not induce cytotoxicity at effective concentrations. JWP24 is applicable for cancer-related research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990774

Verekitug ASP-7266; TRAB-1; UPB-101	Interleukin Related	Inflammation/Immunology
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .

HY-P99505

Ziltivekimab COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216	Interleukin Related LDLR	Inflammation/Immunology Endocrinology
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .

HY-P991400

GSK1995057	TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK	Inflammation/Immunology
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .

HY-P990951

Vixticibart REGN-5381	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .

HY-P990552A

huATN-658	PAI-1 Integrin	Cancer
huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

HY-P990836

Anti-IL-9 Antibody (MH9A4)	Interleukin Related	Inflammation/Immunology
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human IL-9. Anti-IL-9 Antibody (MH9A4) reacts with human IL-9 (interleukin-9) and does not block the binding of IL-9 to the IL-9 receptor. Anti-IL-9 Antibody (MH9A4) can be used for the detection of flow cytometry and ELISA .

HY-P992094

Capromab	PSMA	Cancer
Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .

HY-P991850

Anti-Fibulin-4 Antibody (5G11)	Integrin	Inflammation/Immunology
Anti-Fibulin-4 Antibody (5G11) reacts with the human fibulin-4. Anti-Fibulin-4 Antibody (5G11) does not show any crossreactivity with other family members. Fibulin-4 is an elastic-fibre-associated glycoprotein.

HY-P991838

Anti-CD71 Antibody (T56/14)	Transferrin Receptor	Cancer
Anti-CD71 Antibody (T56/14) reacts with human CD71. Anti-CD71 Antibody (T56/14) is a non-neutralizing antibody that does not inhibit the binding of transferrin. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P992181

AMG-329 MEDI1116; VIB-1116; HZN-1116	Inhibitory Antibodies	Inflammation/Immunology
AMG-329 (MEDI1116) is a human immunoglobulin G1λ monoclonal antibody targeting FLT3L. AMG-329 selectively binds to FLT3L, blocks FLT3L-FLT3 interaction, neutralizes soluble and cell-bound human FLT3L activity. AMG-329 reduces circulating relative proportions of plasmacytoid dendritic cells, conventional dendritic cells, and classical monocytes. AMG-329 does not induce antibody dependent cellular cytotoxicity. AMG-329 can be used for the research of sjögren’s disease .

HY-P992437

PF-03475952	CD44 Apoptosis	Inflammation/Immunology Cancer
PF-03475952 is a fully human IgG2 monoclonal antibody targeting CD44. PF-03475952 binds an epitope in CD44’s constant exons, blocks CD44-hyaluronic acid interaction, reduces cell surface CD44, and does not cross-react with rodent CD44 or LYVE-1. PF-03475952 induces cancer cell apoptosis, inhibits LPS (HY-D1056)-induced leukocyte cytokine release and cancer metastasis, and reduces CD44 expression on circulating CD3+ lymphocytes in cynomolgus monkeys. PF-03475952 can be used for the research of rheumatoid arthritis and hepatocellular carcinoma .

HY-P992056

*Anti-Human/Mouse LY6E Antibody (9B12)*	Autophagy	Cancer
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 ⁺ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 ⁺ T cells strictly depends on the presence of PILRα, and it does not affect CD4 ⁺ T cells or T cell development in the thymus, exhibiting high specificity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2574

Gitogenin 2 Publications Verification	Tribulus terrester Linn. Classification of Application Fields Zygophyllaceae Metabolic Disease Plants Disease Research Fields Steroids Source Classification	Glycosidase
Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC₅₀ values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .

HY-124529

Lunularin	Structural Classification Human Gut Microbiota Metabolites other families Conocephalum conicum (L.) Dumort. Phenols Polyphenols Plants Endogenous metabolite Source Classification	11β-HSD Endogenous Metabolite
Lunularin is an inhibitor of 11β-hydroxysteroid dehydrogenase 1, with an IC₅₀ of 45.44 μM and a K_i of 35.8 μM against human 11β-HSD1, and an IC₅₀ of 17.39 μM and a K_i of 10.31 μM against rat 11β-HSD1. Lunularin upregulates the transcription levels of Sirt1 and Hmox1 genes in the liver. Lunularin reduces food intake and body weight gain, and decreases blood glucose levels in mice fed a high-fat diet. Lunularin inhibits LPS-induced TLR4-mediated NF-κB pathway activation and nitric oxide production. Lunularin inhibits the proliferation and colony formation of renal cancer and colon cancer cells, and exhibits cancer cell-specific cytotoxicity. Lunularin binds to the steroid-binding site of human 11β-HSD1 and the steroid/NADPH-binding region of rat 11β-HSD1, but does not inhibit 11β-HSD2 or mouse 11β-HSD1. Lunularin can be used in research related to diet-induced obesity, renal cancer, colorectal cancer, inflammatory diseases and metabolic syndrome .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Liposome
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-N15135

Arabinoxylan (Medium viscosity)	Structural Classification Polysaccharides Antibiotics Leguminosae Pisum sativum Linn Plants Saccharides Other Antibiotics Source Classification	Interleukin Related Toll-like Receptor (TLR) Fungal
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

HY-111759

Jaspamycin 1 Publications Verification 7-CN-7-C-Ino	Marine natural products Source Classification	PKA Parasite
Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC₅₀ of 6.5 nM and K_d of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity .

HY-B1259

6-Acetamidohexanoic acid Acexamic acid; 6-Acetamidocaproic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Drug Metabolite Drug Intermediate
6-Acetamidohexanoic acid (Acexamic acid; 6-Acetamidocaproic acid) is a metabolite of Hexamethylene bisacetamide (HMBA) (HY-124284) with anti-pulmonary fibrosis activity. 6-Acetamidohexanoic acid does not induce differentiation of human promyelocytic leukemia cells, but is taken up by such cells. 6-Acetamidohexanoic acid serves as a carboxylic acid substrate component for constructing carboxylesterase-responsive near-infrared phototheranostic probes. 6-Acetamidohexanoic acid is applicable to research related to pulmonary fibrosis, refractory hypoxemia and cervical cancer .

HY-145491

Resolvin D5	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	ERK NF-κB CCR
Resolvin D5 is an anti-inflammatory and analgesic agent produced in M2 macrophages. Resolvin D5 alleviates Paclitaxel (HY-B0015)-induced mechanical allodynia and inflammatory pain by activating the GPR32 receptor, with gender specificity (effective only in male mice) and independence from TRPV1 or TRPA1 channels. Resolvin D5 attenuates LPS-induced ERK phosphorylation and NF-κB nuclear translocation, downregulates proinflammatory mediators such as IL-6 and CCL5, inhibits Th17 cell differentiation and osteoclastogenesis, promotes regulatory T cell differentiation, and shows no cytotoxicity to human monocytes. The level of Resolvin D5 is elevated in arthritic SKG mice, but Resolvin D5 has no effect on dendritic cell differentiation or M1 macrophage polarization, nor does it prevent ZyA-induced arthritis progression. Resolvin D5 is suitable for research related to chemotherapy-induced peripheral neuropathy, inflammatory pain and rheumatoid arthritis .

HY-N2574R

Gitogenin (Standard)	Tribulus terrester Linn. Structural Classification Zygophyllaceae Plants Steroids Source Classification	Reference Standards Glycosidase
Gitogenin (Standard) is the analytical standard of Gitogenin. This product is intended for research and analytical applications. Gitogenin is a natural steroid isolated from the whole plant of Tribulus longipetalus. Gitogenin is a selective inhibitor of UDP-glucuronosyltransferase 1A4 (UGT1A4) and enzyme α-glucosidase with IC₅₀ values of 0.69 μM (use trifluoperazine as a substrate) and 37.2 μM, respectively, and does not inhibit the activities of major human cytochrome P450 isoforms .

HY-N19875

Myrseguinoside A	Myrsine seguinii H. Lév. Structural Classification Plants Primulaceae Saccharides Monosaccharides Source Classification	Reactive Oxygen Species (ROS)
Myrseguinoside A is a monoterpene glucoside found in the fruits of Myrsine seguinii. Myrseguinoside A does not exhibit significant DPPH radical-scavenging activity or growth inhibitory activity toward human cancer cells. Myrseguinoside A can be used for cancer research .

HY-N18228

Stauntoside Ⅱ	Apocynaceae Structural Classification Plants Vincetoxicum stauntonii (Decne.) C. Y. Wu et D. Z. Li Steroids Source Classification	Others
Stauntoside Ⅱ is a 14,15-secopregnane-type C21 steroidal glycoside found in the roots of Cynanchum stauntonii. Stauntoside Ⅱ does not exhibit cytotoxic activity against human colon, hepatoma, gastric, lung, and ovarian cancer cells .

HY-N17854

3β-O-α-L-Arabinopyranosylsiaresinolic acid 28-O-β-D-glucopyranosyl ester	Structural Classification Sanguisorba officinalis Linn. Terpenoids Rosaceae Plants Pentacyclic Triterpenoids Source Classification	Drug Derivative
3β-O-α-L-Arabinopyranosylsiaresinolic acid 28-O-β-D-glucopyranosyl ester is a triterpene glycoside found in the roots of Sanguisorba officinalis. 3β-O-α-L-Arabinopyranosylsiaresinolic acid 28-O-β-D-glucopyranosyl ester is non-cytotoxic and does not exhibit cytotoxic activity against human oral squamous cell carcinoma cells or normal human gingival fibroblasts .

HY-N12104

Trichodimerol BMS-182123	Structural Classification Natural Products Endogenous metabolite Source Classification	TNF Receptor
Trichodimerol (BMS-182123) is a TNF-α promoter inhibitor that inhibits the activity of lipopolysaccharide-induced cytokine secretion. Trichodimerol inhibits lipopolysaccharide-induced TNF-α promoter activity, reduces steady-state TNF-α mRNA expression, and does not alter the stability of TNF-α mRNA. Trichodimerol inhibits lipopolysaccharide-induced TNF-α secretion in murine and human immune cells. Trichodimerol reduces lipopolysaccharide-induced IL-1β secretion by 25%-50% in vitro. Trichodimerol does not alter total protein synthesis or constitutive lysozyme secretion at effective concentrations. Trichodimerol can be used for the research of septic shock .

HY-N17444

3β-Hydroxy-24-methylenecholest-5-en-7-one	Triterpenes Structural Classification Animals Terpenoids Source Classification	Others
3β-Hydroxy-24-methylenecholest-5-en-7-one (Compound 4) is a steroid found in the soft coral Sinularia nanolobata. 3β-Hydroxy-24-methylenecholest-5-en-7-one does not exhibit cytotoxic activity against human cancer cells .

HY-N6998A

6-epi-Paederosidic acid	Structural Classification Iridoids Terpenoids Rubiaceae Plants Source Classification Paederia foetida L.	Others
6-epi-Paederosidic acid is a cyclopentanoid monoterpene glycoside found in the aerial parts of Paederia foetida L. 6-epi-Paederosidic acid does not exhibit cytotoxic activity against human tumor cells, hepatoprotective activity against APAP (HY-66005)-induced cellular toxicity, or inhibitory activity against LPS (HY-D1056)-induced nitric oxide production in murine microglia .

HY-N0990

1,5,15-Trimethylmorindol	Anthraquinones Morinda citrifolia Linn. Rubiaceae Plants Source Classification	Others
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .

HY-182569

FR 111142	Structural Classification Natural Products Microorganisms Source Classification	VEGFR
FR 111142 is an angiogenesis inhibitor (IC₅₀ = 18.4 μM) and has anti-inflammatory activity (IC₅₀ = 20.6 μM). FR 111142 inhibits capillary-like tube formation as well as nitric oxide production in LPS (HY-D1056)-activated murine macrophages. FR 111142 enhances catabolism of low-density lipoprotein (LDL). FR 111142 does not induce significant cytotoxicity in human endothelial progenitor cells, nor affect cell viability of murine macrophages. FR 111142 can be used for the research of cancer, inflammatory diseases .

HY-B1259R

6-Acetamidohexanoic acid (Standard) Acexamic acid (Standard); 6-Acetamidocaproic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Drug Metabolite Drug Intermediate
6-Acetamidohexanoic acid (Acexamic acid; 6-Acetamidocaproic acid) (Standard) is the analytical standard of 6-Acetamidohexanoic acid. This product is intended for research and analytical applications. 6-Acetamidohexanoic acid (Acexamic acid; 6-Acetamidocaproic acid) is a metabolite of Hexamethylene bisacetamide (HMBA) (HY-124284) with anti-pulmonary fibrosis activity. 6-Acetamidohexanoic acid does not induce differentiation of human promyelocytic leukemia cells, but is taken up by such cells. 6-Acetamidohexanoic acid serves as a carboxylic acid substrate component for constructing carboxylesterase-responsive near-infrared phototheranostic probes. 6-Acetamidohexanoic acid is applicable to research related to pulmonary fibrosis, refractory hypoxemia and cervical cancer.

HY-N13838

8,9-Dehydro-7,9-diisobutyryloxythymol	Triterpenes Structural Classification Pongamia pinnata (L.) Pierre Terpenoids Plants Compositae Source Classification	Bacterial
8,9-Dehydro-7,9-diisobutyryloxythymol is a Thymol (HY-N6810) derivative, as well as an antibacterial agent. 8,9-Dehydro-7,9-diisobutyryloxythymol can be found in the aerial parts of Ageratina adenophora, with selective activity against Gram-positive bacterial strains including Bacillus cereus. 8,9-Dehydro-7,9-diisobutyryloxythymol does not exhibit detectable in vitro cytotoxic activity against human cancer cell lines. 8,9-Dehydro-7,9-diisobutyryloxythymol can be used for the research of bacterial infection .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702402

	*OPRD1 Protein, Human* (Cell-Free, His)** Delta-type opioid receptor; D-OR-1; DOR-1	Human	E. coli Cell-free
	The OPRD1 protein is a G protein-coupled receptor for enkephalins and opioids that undergoes ligand-induced conformational changes to activate signaling through G proteins and inhibit adenylate cyclase. Additionally, it reduces neurotransmitter release by affecting ionic currents. OPRD1 Protein, Human (Cell-Free, His) is the recombinant human-derived OPRD1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-126356S

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d₁₁ is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (HY-126356). 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

Cat. No.	Product Name		Classification

HY-174637

Human IL13RA2 mRNA		mRNA Interleukin & Receptors
Human IL13RA2 mRNA encodes the human interleukin 13 receptor subunit alpha 2 (IL13RA2) protein, a subuint of the interleukin 13 receptor complex. IL13RA2 binds IL13 with high affinity, but lacks cytoplasmic domain, and does not appear to function as a signal mediator. It is reported to play a role in the internalization of IL13.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

human DOR

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products